Breaking News

You are here » Indian-Commodity  :  Commodities  :  Jeera  :  Jeera futures decline on NCDEX

14-Feb2018

Jeera futures decline on NCDEX

Jeera futures declined on NCDEX, as market players liquidated their holdings on anticipation of higher production and start of new season arrivals amid reports of higher acreage of cumin.

The contract for March delivery was trading at Rs 15965.00, lower by 0.81% or Rs 130.00 from its previous closing of Rs 16095.00. The open interest of the contract stood at 10560 lots.

The contract for April delivery was trading at Rs 16240.00, down 0.95% or Rs 155.00 from its previous closing of Rs 16395.00. The open interest of the contract stood at 1968 lots on NCDEX.


Related News

View all news

Jeera futures trade bearish on profit taking

Jeera futures traded bearish on NCDEX, with the profit booking by investors after the cumin prices rose due to firm physical domestic and exports demands from China and Bangladesh coupled......

Jeera futures surge on production concern

Jeera futures surged on NCDEX, due to technical buying by stockists and retailers amid expectations of lower production with the scanty rains in the cumin producing districts of Gujarat. Moreover, steady......

Jeera futures trade lower on NCDEX

Jeera futures traded lower on NCDEX, as traders locked-in their gains in conjunction with dip in export demands at prevailing higher price levels. Further, increased arrivals and good stocks also weighed......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......